REFERENCES
- CA Bernhart, PM Perreaut, BP Ferrari, YA Muneaux, J-L Assens, J Clement, F Haudricourt, CF Muneaux, JE Taillades, M-A Vignal, J Gougat, PR Guiraudou, CA Lacour, A Roccoon, CF Cazaubon, J-C Breliere, G Le Fur, and D. A Nisata. (1993). new series of imidazolones: Highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists. J. Med. Chem. 36:3371–3380.
- MA Olson, PG Cummings, S Kennedy-Gabb, BM Wagner, GR Nicol, and B Munson. (2000). The use of deuterium oxide as a mobile phase for structural elucidation by HPLC/UV/ESI/MS. Anal. Chem. 72 (20):5070–5078.
- JH Espenson. Chemical Kinetics and Reaction Mechanisms. McGraw-Hill, Singapore, (1995).
- SF Dyke. The Chemistry of Enamines. Cambridge University Press (1973)10.
- FA Carey, and RJ Sundberg. Advanced Organic Chemistry, Part B: Reaction and Synthesis3rd. Plenum Publishing Corporation, New York, (1991)31–40.
- R Frontini, and JB Mielck. (1995). Formation of formaldehyde in polyethylene glycol and in poloxamer under stress conditions. Int. J. Pharm. 114:121–123.
- DM Johnson, and WF Taylor. (1984). Degradation of fenprostalene in polyethylene glycol 400 solution. J. Pharm. Sci. 73:1414–1417.
- JW McGinity, JA Hill, and AL LaVia. (1975). Influence of peroxide impurities in polyethylene glycols on drug stability. J. Pharm. Sci. 64:356–357.
- JW McGinity, TR Patel, and AH Naqvi. (1976). Implications of peroxide formation in lotion and ointment dosage forms containing polyethylene glycols. Drug Dev. Commun. 2 (26):505–519.
- DS Bindra, TD Williams, and VJ Stella. (1994). Degradation of O6-benzylquanine in aqueous polyethylene glycol (PEG 400) solutions: Concerns with Formaldehyde in PEG 400. Pharm. Res. 11:1060–1064.
- M Bergh, K Magnusson, JLG Nilsson, and A-T Karlberg. (1998). Formation of formaldeyhde and peroxides by air oxidation of high purity polyoxyethylene surfactants. Contact Dermatitis 39:14–20.
- MN Nassar, VN Nesarikar, R Lozano, WL Parker, Y Huang, V Palaniswamy, W Xu, and N Khaselev. (2004). Influence of Formaldehyde Impurity in Polysorbate 80 and PEG 300 on the Stability of a Parenteral Formulation of BMS-204352: Indentification and Control of the Degradation Product. Pharmac. Develop. Technol. 9 (2):189–195.